title: Impact of omalizumab on medical cost of childhood asthma in Japan.
abstract: Omalizumab is effective in children with severe asthma, but its impact on medical cost in Japan is not clear. We evaluated the impact of omalizumab on medical cost by comparing the pre- vs post-omalizumab-initiation medical costs of 12 children with severe asthma who received omalizumab for 2 years, and calculating incremental cost-effectiveness ratio for omalizumab therapy. Health outcome was measured as hospital-free days (HFD). The median total medical costs and medication fee per patient increased significantly after omalizumab initiation because of the high cost of omalizumab. The median hospitalization fee per patient, however, decreased significantly after omalizumab initiation due to reduction in hospitalization. Omalizumab led to an estimated increase of 40.8 HFD per omalizumab responder patient per 2 years. The cost was JPY 20 868 per additional HFD. Omalizumab can therefore reduce hospitalization cost in children with severe asthma in Japan.
authors.affiliation: Department of Pediatrics, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.
authors.forename: Hideki
authors.initials: H
authors.lastname: Yoshikawa
authors.affiliation: Department of Pediatrics, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.
authors.forename: Mihoko
authors.initials: M
authors.lastname: Iwata
authors.affiliation: Department of Pediatrics, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsuzaki
authors.affiliation: Department of Pediatrics, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.
authors.forename: Rintaro
authors.initials: R
authors.lastname: Ono
authors.affiliation: Department of Pediatrics, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.
authors.forename: Yoko
authors.initials: Y
authors.lastname: Murakami
authors.affiliation: Department of Pediatrics, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.
authors.forename: Naohiko
authors.initials: N
authors.lastname: Taba
authors.affiliation: Department of Pediatrics, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.
authors.forename: Satoshi
authors.initials: S
authors.lastname: Honjo
authors.affiliation: Department of Pediatrics, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.
authors.forename: Chikako
authors.initials: C
authors.lastname: Motomura
authors.affiliation: Department of Pediatrics, National Hospital Organization Fukuoka Hospital, Fukuoka, Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Odajima
mesh_terms: D000293:Adolescent; D018927:Anti-Asthmatic Agents / Q000191:economics* / Q000627:therapeutic use; D001249:Asthma / Q000188:drug therapy* / Q000191:economics*; D002648:Child; D003362:Cost-Benefit Analysis; D005260:Female; D017048:Health Care Costs / Q000706:statistics & numerical data*; D006760:Hospitalization / Q000191:economics / Q000706:statistics & numerical data; D006801:Humans; D007564:Japan; D008297:Male; D000069444:Omalizumab / Q000191:economics* / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D018927:Anti-Asthmatic Agents; D000069444:Omalizumab
keywords: Japan; asthma; medical cost; omalizumab; pediatrics